Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             118 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Academic HTS: diverse portraits Nelson, Sandra L.
 2008
 32-33 1 p. e29-e33
nvt p.
 artikel
2 A critical assessment of the potential of short interfering RNA therapeutics Stein, C.A.
 2005
 32-33 1 p. 27-31
5 p.
 artikel
3 A Drosophila approach to thyroid cancer therapeutics Das, Tirtha K.
 2013
 32-33 1 p. e65-e71
nvt p.
 artikel
4 All-hydrocarbon stapled peptides as Synthetic Cell-Accessible Mini-Proteins Verdine, Gregory L.
 2012
 32-33 1 p. e41-e47
nvt p.
 artikel
5 Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity Lublin, A.L.
 2013
 32-33 1 p. e115-e119
nvt p.
 artikel
6 Analysis of complex, multidimensional datasets Girolami, Mark
 2006
 32-33 1 p. 13-19
7 p.
 artikel
7 Animal models in therapeutic drug discovery for oculopharyngeal muscular dystrophy Chartier, Aymeric
 2013
 32-33 1 p. e103-e108
nvt p.
 artikel
8 An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs Rocheville, Magalie
 2010
 32-33 1 p. e87-e94
nvt p.
 artikel
9 An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path Initiative Tong, Weida
 2007
 32-33 1 p. 3-8
6 p.
 artikel
10 Assessment of drug-induced immunotoxicity in animal models van Wijk, Femke
 2006
 32-33 1 p. 103-109
7 p.
 artikel
11 Beyond cell penetrating peptides: designed molecular transporters Wender, Paul A.
 2012
 32-33 1 p. e49-e55
nvt p.
 artikel
12 Biocatalytic synthesis of enantiopure building blocks for pharmaceuticals Simon, Robert C.
 2013
 32-33 1 p. e37-e44
nvt p.
 artikel
13 Biomarkers for pharmacogenetic and pharmacogenomic studies: Locking down analytical performance Mansfield, Elizabeth
 2007
 32-33 1 p. 17-20
4 p.
 artikel
14 Biomarkers for pharmacogenetic and pharmacogenomic studies: special issues in analytical performance Mansfield, Elizabeth
 2007
 32-33 1 p. 21-24
4 p.
 artikel
15 Buccal drug delivery: A challenge already won? Rossi, Silvia
 2005
 32-33 1 p. 59-65
7 p.
 artikel
16 Catalytic asymmetric alkylation of ketones using organometallic reagents Madduri, Ashoka V.R.
 2013
 32-33 1 p. e21-e27
nvt p.
 artikel
17 Cell-based assays for kinase drug discovery Smith, Gary K.
 2010
 32-33 1 p. e13-e19
nvt p.
 artikel
18 Chemical kinomics – a target gene family approach in chemical biology Klebl, Bert M.
 2004
 32-33 1 p. 25-34
10 p.
 artikel
19 Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders Sarkar, Sovan
 2013
 32-33 1 p. e137-e144
nvt p.
 artikel
20 Chitosan and the mucosal delivery of biotechnology drugs Issa, Mohamed M.
 2005
 32-33 1 p. 1-6
6 p.
 artikel
21 Colonic drug delivery Rubinstein, Abraham
 2005
 32-33 1 p. 33-37
5 p.
 artikel
22 Contents 2008
 32-33 1 p. i-
1 p.
 artikel
23 Contents 2006
 32-33 1 p. i-
1 p.
 artikel
24 Contents 2005
 32-33 1 p. i-ii
nvt p.
 artikel
25 Contents 2004
 32-33 1 p. i-
1 p.
 artikel
26 Contents 2007
 32-33 1 p. i-
1 p.
 artikel
27 Continuous flow synthesis Yoshida, Jun-ichi
 2013
 32-33 1 p. e53-e59
nvt p.
 artikel
28 Determination of inflammatory biomarkers by immunoaffinity capillary electrophoresis Guzman, Norberto A.
 2006
 32-33 1 p. 29-37
9 p.
 artikel
29 Discovery and applications of naturally occurring cyclic peptides Thorstholm, L.
 2012
 32-33 1 p. e13-e21
nvt p.
 artikel
30 Discovery of therapeutic targets by phenotype-based zebrafish screens Peterson, Randall T.
 2004
 32-33 1 p. 49-54
6 p.
 artikel
31 Display considerations for quantitative radiology Badano, Aldo
 2007
 32-33 1 p. 29-32
4 p.
 artikel
32 Drug metabolism in silico – the knowledge-based expert system approach. Historical perspectives and current strategies Long, Anthony
 2013
 32-33 1 p. e147-e153
nvt p.
 artikel
33 Editorial 2006
 32-33 1 p. 1-3
3 p.
 artikel
34 Editorial 2005
 32-33 1 p. iii-iv
nvt p.
 artikel
35 Editorial for HTS revisited Gribbon, Phillip
 2008
 32-33 1 p. e1-
1 p.
 artikel
36 End-capped α-helices as modulators of protein function Mahon, Andrew B.
 2012
 32-33 1 p. e57-e62
nvt p.
 artikel
37 Enhancing exposure of protein therapeutics Beals, John M.
 2006
 32-33 1 p. 87-94
8 p.
 artikel
38 Epigenetic control of the immune system: histone demethylation as a target for drug discovery Lora, Jose M.
 2010
 32-33 1 p. e67-e75
nvt p.
 artikel
39 Epigenetics: tools and technologies Janzen, William P.
 2010
 32-33 1 p. e59-e65
nvt p.
 artikel
40 Evolution in thinking and processes? Sewing, Andreas
 2008
 32-33 1 p. e9-e14
nvt p.
 artikel
41 Exposition and reactivity optimization to predict sites of metabolism in chemicals Cruciani, Gabriele
 2013
 32-33 1 p. e155-e165
nvt p.
 artikel
42 FDA's Critical Path Initiative Woodcock, Janet
 2007
 32-33 1 p. 1-
1 p.
 artikel
43 FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus Pinkos, Arleen
 2007
 32-33 1 p. 25-28
4 p.
 artikel
44 Fishing for targets: novel approaches using small molecule baits Szardenings, Katrin
 2004
 32-33 1 p. 9-15
7 p.
 artikel
45 Fixing clearance as early as lead optimization using high throughput in vitro incubations in combination with exact mass detection and automatic structure elucidation of metabolites Zimmerlin, Alfred
 2013
 32-33 1 p. e191-e198
nvt p.
 artikel
46 Glycomics – a new target for pharmaceuticals Nakano, Miyako
 2006
 32-33 1 p. 39-47
9 p.
 artikel
47 Gold-catalyzed formation of heterocycles – an enabling new technology for medicinal chemistry Shen, Hong C.
 2013
 32-33 1 p. e3-e14
nvt p.
 artikel
48 G protein-coupled receptor kinases: Specific phosphorylation of 7TM receptors and beyond Murga, C.
 2010
 32-33 1 p. e43-e49
nvt p.
 artikel
49 β-Hairpin protein epitope mimetic technology in drug discovery Obrecht, Daniel
 2012
 32-33 1 p. e63-e69
nvt p.
 artikel
50 High-throughput, computer assisted, specific MetID. A revolution for drug discovery Zamora, Ismael
 2013
 32-33 1 p. e199-e205
nvt p.
 artikel
51 High-throughput hit finding and compound-profiling technologies for academic drug discovery Gribbon, Philip
 2008
 32-33 1 p. e3-e7
nvt p.
 artikel
52 Identifying orphan G protein coupled receptors in drug discovery Dunlop, John
 2004
 32-33 1 p. 61-68
8 p.
 artikel
53 Image-based high-content reporter assays: limitations and advantages Gasparri, Fabio
 2010
 32-33 1 p. e21-e30
nvt p.
 artikel
54 Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI) Kamel, Amin
 2013
 32-33 1 p. e177-e189
nvt p.
 artikel
55 Innovative methods in drug regulatory sciences Leufkens, Hubert (Bert) G.
 2011
 32-33 1 p. e1-e2
nvt p.
 artikel
56 In vivo strategies for drug discovery in myotonic dystrophy disorders Garcia-Alcover, Irma
 2013
 32-33 1 p. e97-e102
nvt p.
 artikel
57 Ion channel screening – automated patch clamp on the rise Farre, Cecilia
 2008
 32-33 1 p. e23-e28
nvt p.
 artikel
58 Is quantitative benefit–risk modelling of drugs desirable or possible? Phillips, Lawrence D.
 2011
 32-33 1 p. e3-e10
nvt p.
 artikel
59 Knottins: disulfide-bonded therapeutic and diagnostic peptides Moore, Sarah J.
 2012
 32-33 1 p. e3-e11
nvt p.
 artikel
60 Label-free receptor assays Fang, Ye
 2010
 32-33 1 p. e5-e11
nvt p.
 artikel
61 Mass spectrometric analysis of intact macromolecular chaperone complexes van Duijn, Esther
 2006
 32-33 1 p. 21-27
7 p.
 artikel
62 Mass spectrometry techniques for qualitative and quantitative analysis of biomarkers Drexler, Dieter M.
 2004
 32-33 1 p. 17-23
7 p.
 artikel
63 Mechanistic pharmacology, new developments Wise, Alan
 2010
 32-33 1 p. e1-e3
nvt p.
 artikel
64 Metabolites: structure determination and prediction Cruciani, Gabriele
 2013
 32-33 1 p. e145-e146
nvt p.
 artikel
65 Metabolomic biomarkers: their role in the critical path Schnackenberg, Laura K.
 2007
 32-33 1 p. 13-16
4 p.
 artikel
66 Metal-free bioconjugation reactions van Berkel, Sander S.
 2013
 32-33 1 p. e45-e51
nvt p.
 artikel
67 Miniaturization: Chip-based liquid chromatography and proteomics Gauthier, Georges L.
 2006
 32-33 1 p. 59-66
8 p.
 artikel
68 Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies Markstein, Michele
 2013
 32-33 1 p. e73-e81
nvt p.
 artikel
69 Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity Carosati, Emanuele
 2013
 32-33 1 p. e167-e175
nvt p.
 artikel
70 Model organisms and target discovery Muda, Marco
 2004
 32-33 1 p. 55-59
5 p.
 artikel
71 Model organisms offer new possibilities for discovery of therapeutics Draper, Isabelle
 2013
 32-33 1 p. e61-e64
nvt p.
 artikel
72 Modern analytical technologies for the detection of drug abuse and doping Huestis, Marilyn A.
 2006
 32-33 1 p. 49-57
9 p.
 artikel
73 Molecular imprinting: A new tool for drug innovation van Nostrum, Cornelus F.
 2005
 32-33 1 p. 119-124
6 p.
 artikel
74 Molecular motors as drug delivery vehicles Cohen, Richard N.
 2005
 32-33 1 p. 111-118
8 p.
 artikel
75 Mucoadhesive systems in oral drug delivery Bernkop-Schnürch, Andreas
 2005
 32-33 1 p. 83-87
5 p.
 artikel
76 Multicomponent reactions – opportunities for the pharmaceutical industry Ruijter, Eelco
 2013
 32-33 1 p. e15-e20
nvt p.
 artikel
77 Nanoparticle uptake by the oral route: Fulfilling its potential? Florence, Alexander T.
 2005
 32-33 1 p. 75-81
7 p.
 artikel
78 New approaches to strengthen pharmacovigilance Arlett, Peter R.
 2011
 32-33 1 p. e15-e19
nvt p.
 artikel
79 New poly(lactic-co-glycolic acid) derivatives: Modular polymers with tailored properties Dailey, Lea Ann
 2005
 32-33 1 p. 7-13
7 p.
 artikel
80 New synthetic technologies Rutjes, Floris
 2013
 32-33 1 p. e1-e2
nvt p.
 artikel
81 New technologies for assessing UDP-glucuronosyltransferase (UGT) metabolism in drug discovery and development Patten, Christopher J.
 2006
 32-33 1 p. 73-78
6 p.
 artikel
82 Nonviral gene delivery systems: From simple transfection agents to artificial viruses Mastrobattista, Enrico
 2005
 32-33 1 p. 103-109
7 p.
 artikel
83 Novel biomarker platforms in toxicology Shaw, Martin
 2006
 32-33 1 p. 95-102
8 p.
 artikel
84 On the edge of new technologies (advanced therapies, nanomedicines) Vamvakas, Spiros
 2011
 32-33 1 p. e21-e28
nvt p.
 artikel
85 Opioid peptides: potential for drug development Aldrich, Jane V.
 2012
 32-33 1 p. e23-e31
nvt p.
 artikel
86 Organocatalytic methods for CC bond formation Mahrwald, Rainer
 2013
 32-33 1 p. e29-e36
nvt p.
 artikel
87 Patient opinions and preferences in drug development and regulatory decision making Breckenridge, Alasdair
 2011
 32-33 1 p. e11-e14
nvt p.
 artikel
88 Pepducins: lipopeptide allosteric modulators of GPCR signaling Carlson, Kenneth E.
 2012
 32-33 1 p. e33-e39
nvt p.
 artikel
89 Peptides or modified peptides as drug molecules Carney, S.L.
 2012
 32-33 1 p. e1-e2
nvt p.
 artikel
90 Performance-driven, pulmonary delivery of systemically acting drugs Vanbever, Rita
 2005
 32-33 1 p. 39-46
8 p.
 artikel
91 Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease Tardiff, Daniel F.
 2013
 32-33 1 p. e121-e128
nvt p.
 artikel
92 Physiology-based pharmacokinetic modeling: ready to be used Schmitt, Walter
 2005
 32-33 1 p. 125-132
8 p.
 artikel
93 Population genetics for target identification Healy, Daniel G.
 2004
 32-33 1 p. 69-74
6 p.
 artikel
94 Post-innovation innovation of medicinal products Leufkens, Hubert (Bert) G.
 2011
 32-33 1 p. e37-e41
nvt p.
 artikel
95 Proteomics: how to control highly dynamic patterns of millions of molecules and interpret changes correctly? Schrattenholz, André
 2004
 32-33 1 p. 1-8
8 p.
 artikel
96 Questions and answers about the Pilot Process for Biomarker Qualification at the FDA Goodsaid, Federico M.
 2007
 32-33 1 p. 9-11
3 p.
 artikel
97 Rationale and benefit of using high throughput solubility screens in drug discovery Goodwin, Joseph J.
 2006
 32-33 1 p. 67-71
5 p.
 artikel
98 Recent applications of protein arrays in target identification and disease monitoring Witte, Krista L.
 2004
 32-33 1 p. 35-40
6 p.
 artikel
99 Seeking ligand bias: assessing GPCR coupling to β-arrestins for drug discovery Bohn, Laura M.
 2010
 32-33 1 p. e37-e42
nvt p.
 artikel
100 Shaping biodegradable polymers as nanostructures: Fabrication and applications Lu, Yi
 2005
 32-33 1 p. 97-102
6 p.
 artikel
101 Smart polymeric micelles for gene and drug delivery Nishiyama, Nobuhiro
 2005
 32-33 1 p. 21-26
6 p.
 artikel
102 Software aided approaches to structure-based metabolite identification in drug discovery and development Pähler, Axel
 2013
 32-33 1 p. e207-e217
nvt p.
 artikel
103 Soluble polymer conjugates for drug delivery Minko, Tamara
 2005
 32-33 1 p. 15-20
6 p.
 artikel
104 Stem cells, immortalized cells and primary cells in ADMET assays Sinz, Michael W.
 2006
 32-33 1 p. 79-85
7 p.
 artikel
105 Subcutaneous drug delivery and the role of the lymphatics McLennan, Danielle N.
 2005
 32-33 1 p. 89-96
8 p.
 artikel
106 The impact of physical based methods screening and their delivery of better quality hits Kahmann, Jan
 2008
 32-33 1 p. e15-e22
nvt p.
 artikel
107 The use of affinity sorbents in targeted proteomics Freije, J. Robert
 2006
 32-33 1 p. 5-11
7 p.
 artikel
108 Tissue microarrays for early target evaluation Simon, Ronald
 2004
 32-33 1 p. 41-48
8 p.
 artikel
109 Trends in the technology-driven development of new inhalation devices Frijlink, Henderik W.
 2005
 32-33 1 p. 47-57
11 p.
 artikel
110 Uncovering GPCR heteromer-biased ligands Mustafa, Sanam
 2010
 32-33 1 p. e77-e85
nvt p.
 artikel
111 Use of functional assays to detect and quantify functional selectivity Clarke, William P.
 2010
 32-33 1 p. e31-e36
nvt p.
 artikel
112 Use of small RNAs for therapeutic gene silencing: risk versus benefit Börner, Kathleen
 2010
 32-33 1 p. e51-e57
nvt p.
 artikel
113 Using Drosophila as a tool to identify pharmacological therapies for fragile X syndrome McBride, Sean M.J.
 2013
 32-33 1 p. e129-e136
nvt p.
 artikel
114 Vesicles as a tool for transdermal and dermal delivery Honeywell-Nguyen, P. Loan
 2005
 32-33 1 p. 67-74
8 p.
 artikel
115 Weighing benefit–risk of medicines: concepts and approaches Mt-Isa, Shahrul
 2011
 32-33 1 p. e29-e35
nvt p.
 artikel
116 Zebrafish-based small molecule screens for novel cardiovascular drugs Novodvorsky, Peter
 2013
 32-33 1 p. e109-e114
nvt p.
 artikel
117 Zebrafish based small molecule screens for novel DMD drugs Kawahara, Genri
 2013
 32-33 1 p. e91-e96
nvt p.
 artikel
118 Zebrafish cancer and metastasis models for in vivo drug discovery Tat, Jennifer
 2013
 32-33 1 p. e83-e89
nvt p.
 artikel
                             118 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland